These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial. Nielsen JS; Chang A; Holekamp NM; Cavichini-Cordeiro M; Lin SL; Heinrich D; Maass KF; Menezes A; Singh N; Pieramici DJ Ophthalmol Retina; 2024 Dec; 8(12):1127-1139. PubMed ID: 38914294 [TBL] [Abstract][Full Text] [Related]
7. The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema. Maguire M; Laidlaw D; Davies N; Hammond C Graefes Arch Clin Exp Ophthalmol; 2024 Nov; 262(11):3501-3508. PubMed ID: 38771336 [TBL] [Abstract][Full Text] [Related]
15. Quantitative Multimodal Imaging Characterization of Intraretinal Cysts versus Degenerative Pseudocysts in Neovascular Age-Related Macular Degeneration. Arrigo A; Aragona E; Battaglia Parodi M; Bandello F Ophthalmol Retina; 2024 Dec; 8(12):1118-1126. PubMed ID: 38848872 [TBL] [Abstract][Full Text] [Related]
16. Investigation of choroidal structure changes after intravitreal anti-VEGF therapy for retinal vein occlusion. Dursun E; Derhem B; Çobanoğlu S; Oğurel T Graefes Arch Clin Exp Ophthalmol; 2024 Dec; 262(12):3837-3845. PubMed ID: 39037469 [TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy. Dervenis P; Dervenis N; Smith JM; Steel DH Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074 [TBL] [Abstract][Full Text] [Related]
18. What Are the Functional, Radiographic, and Survivorship Outcomes of a Modified Cup-cage Technique for Pelvic Discontinuity? Mu W; Xu B; Wahafu T; Wang F; Guo W; Zou C; Cao L Clin Orthop Relat Res; 2024 Dec; 482(12):2149-2160. PubMed ID: 38991223 [TBL] [Abstract][Full Text] [Related]
19. BNT162b2 vaccine booster dose did not influence the activity of the exudative form of age-related macular degeneration during anti-vascular endothelial growth factor therapy. Płatkowska-Adamska B; Bociek A; Kal M; Zarębska-Michaluk D; Odrobina D Minerva Med; 2024 Dec; 115(6):643-650. PubMed ID: 39392292 [TBL] [Abstract][Full Text] [Related]